Evidence map›Paper›PMID 20804502›Full record

ArticleCancer science2010

A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.

Kohsuke Okita, Shinichiro Motohashi, Ryo Shinnakasu, Kaoru Nagato, Kazuki Yamasaki, Yasunori Sato, Hiroshi Kitamura, Atsushi Hijikata, Masakatsu Yamashita, Kanako Shimizu and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. A Decade of GWAS Results in Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Kohsuke OkitaDepartment of Immunology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Shinichiro Motohashi
Ryo Shinnakasu
Kaoru Nagato
Kazuki Yamasaki
Yasunori Sato
Hiroshi Kitamura
Atsushi Hijikata
Masakatsu Yamashita
Kanako Shimizu
Shin-Ichiro Fujii
Osamu Ohara
Masaru Taniguchi
Isao Sakaida
Toshinori Nakayama
Chiba University · JPChiba University Hospital · JPRIKEN Center for Integrative Medical Sciences · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invariant natural killer T (iNKT) cells possess potent antitumor effects after activation with a specific glycolipid antigen, α-galactosylceramide (αGalCer). A phase I-II clinical study of αGalCer-pulsed dendritic cells (DC) to activate endogenous iNKT cells was previously performed in patients with non-small-cell lung cancer (NSCLC). In this clinical trial, the patients with increased interferon-γ (IFN-γ) production (>two-fold) in PBMC after the DC treatment (good responder group) experienced a prolonged overall survival time in comparison with the poor responder group. We extended the previous study and performed a microarray-based gene expression analysis using peripheral blood CD56(+) cells and CD56(-) CD3(+) T cells from patients enrolled in the above-mentioned clinical study. We sought to identify any biomarkers associated with the immune responses in this immunotherapy trial. Six patient samples corresponding to three subjects in the good responder group and three subjects in the poor responder group were included in the microarray analysis. Genes differentially expressed between pre-treatment and post-treatment samples were selected for analysis. Subsequently, genes that were only expressed in the good responder group or poor responder group were chosen. After these procedures, four selected genes were quantified by reverse transcriptase-polymerase chain reaction in another eight patient samples, and two genes, LTB4DH and DPYSL3, were confirmed to be candidate genes for the predictor of a good immune response. The expression profile of these two genes may be associated with the responsiveness of IFN-γ production after αGalCer-pulsed DC treatment.

Indexed as

Gene Expression ProfilingAdultAgedAlcohol OxidoreductasesCarcinoma, Non-Small-Cell LungCD3 ComplexCD56 AntigenClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicCluster AnalysisDendritic CellsFemaleGalactosylceramidesGenetic Predisposition to DiseaseHumansImmunotherapy, AdoptiveAlcohol OxidoreductasesCD3 ComplexCD56 AntigenDPYSL3 protein, humanGalactosylceramidesInterferon-gammaleukotriene B4 12-hydroxydehydrogenaseMuscle Proteins

Identifiers

PMID20804502
PMCPMC11159413
OpenAlexW2019059672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.